Fundraising FoxAgent Capital — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Cyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning.
AI & Machine LearningBiotechDeep TechSeattle, US
Yifan Song(CSO)inDavid Baker(Co-founder)Javier Castellanos(Executive Officer, Director)inMark(President & EVP, Business Development)
BoardLucas Nivon(CEO)in
Co-investorsAlumni VenturesAnzu PartnersArgonautic VenturesiSelect FundOrbiMedSPRINGROCK VENTURES+4 more
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsDC Investment PartnersLifelinkLongwood FundM VenturesMedical Excellence CapitalNovartis Venture Fund+5 more
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsQuan CapitalBain Capital Life Sciences+3 more
Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.
BiotechDeep TechMedical DevicesPhiladelphia, US
Nicholas Siciliano(Director)inPreston Noon(Executive Officer)
BoardGeeta Vemuri(Executive Officer, Director)Bruce Peacock(Executive Officer, Director)Leon Moulder(Director)
Co-investorsBioAdvanceGlobal BioAccess FundHatch BioFund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.